Koers Tenax Therapeutics Inc Nasdaq
Aandelen
US88032L1008
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 7,52 mln. 6,99 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -16 mln. -14,87 mln. | Nettowinst (verlies) 2025 * | -18 mln. -16,73 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,52
x | K/w-verhouding 2025 * |
-1,06
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,65% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 50 | 14-07-21 | |
Director of Finance/CFO | 69 | 11/01 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 15-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 04-04-14 |
June Almenoff
BRD | Director/Board Member | 67 | 25-02-21 |
Declan Doogan
BRD | Director/Board Member | 72 | 25-02-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,9 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |